Report Overview

Indian Osteoporosis Drugs Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period (2019-2028).

India is the Osteoporosis capital of the world. It is a very common problem. Certain medications also help to increase the rate of bone loss, including some anti-seizure medications, proton pump inhibitors, chemotherapy, selective serotonin reuptake inhibitors, and glucocorticosteroids. The rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc. are the major factors contributing towards the growth of osteoporosis drugs market.



Market Drivers

Increasing prevalence of diseases such as cancer, autoimmune disorders, thalassemia with geriatric population, rise in healthcare expenditure, lifestyle associated factors such as alcohol abuse, sedentary lifestyle, rapid increase in the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care and increasing investment in drug discovery and development are the other factors supplementing the growth of osteoporosis drugs market.